Tipperenx
Gilead Sciences or Biogen: Which Biotech Stock is the Better Choice for 2021?
The unprecedented epidemic did not stop the US stock market from ending 2020 on a 20 note. The S&P 500 ended the most volatile year at an overall high and overall, up 16.3%. Meanwhile, some stocks in the healthcare sector have seen attractive returns for investors. However, that list does not include Gilead Sciences and Biogen. Does Wall Street expect a recovery of these stocks this year? Gilad Sciences (GILD) and Gilead Sciences made headlines last year for its antiviral drug Remedesivir (when sold under the brand). In May, the UPFDA (Food and Drug Administration) approved the emergency use of the name Vaccuri for the treatment of Cockmid-19. October In October 2020, Remdesivir became the first FDA-accredited treatment for Covid-19 patients in the U.S. The company produced higher-than-expected results in 3Q, mainly due to RemDesivir, which sold in at 873 million and ran more than 17%, increasing overall QQ revenue by 6 6.6 billion. Gilead’s 3Q adjusted EPS rose 29% year-over-year to 11 2.11. (See GILD stock analysis on Tipranx) However, the company has raised its 2020 revenue forecast to 23 23 billion. Streamlined in the range of .5 23.5 billion, which is 23 23 billion-$ 25 billion from a previous point of view, and warned that remedial revenue is subject to significant volatility and uncertainty. . In addition, its hepatitis C virus (HCV) business is under constant pressure amid epidemics. Gilead has a strong portfolio of HIV, including its lead drug, Bictarvi. HIV Sales of products grew by Q%. billion and accounted for 70% of the company’s total product sales. He said there are concerns about the sale of the HIV drug Truvada due to the loss of exclusivity. Meanwhile, the company is strengthening its business through strategic acquisitions in key development areas such as oncology. Last year, Gilead acquired Immunomidics for 21 billion. In the acquisition, FDA-approved metastatic triple-negative breast cancer treatment, Trodelvi, was added to Gilead’s portfolio. The company also acquired clinical-stage immuno-oncology company Forty Seven for 20 20.9 billion in 2020. Recently, Gilead announced an agreement to acquire German Biotech MYR GmbH, which is focused on therapeutic development for the treatment of chronic hepatitis delta virus. After a meeting with regulators, Gilead announced in December that it would not seek FDA approval of filegotinib as a treatment for arthritis in the US. The company entered into a new agreement with partner Galapagos, under which the latter will handle full responsibility for filgotinib in Europe, where doses of 200 mg and 100 mg are approved for the treatment of moderate to severe rheumatoid arthritis, and all indications for the future. In response to this growth, Oppenheimer analyst Hartaj Singh lowered his price target from 105 dollars to 100 dollars. However, the analyst reiterated the rating he bought on Gilead because it was up against the stork-covi flair “(1) a trusted remedial / other drug business, (2) growing in the base business (HIV / oncology / HCV). In the next few years low-single digits, ()) operating operating leverage provides higher earnings growth, and ())% – %% dividend yield. “Currently, the rest of the street is moderately optimistic with the middle buy analyst. Consensus based on 10 by, 12 hold and 1 cell. The average price target of Price 74 indicates a potential upside of 27% above current levels. Shares are down 10.4% in 2020. Biogen (BIIB) 2020 was a difficult year for Biogen, who specializes in the treatment of neurological disorders. The company was shocked in November when the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted against the effectiveness of antibodies to treat Alzheimer’s disease. Investors saw the news as a big sell-off in biogen stocks. Edukunumb as a potential blockbuster drug for the company. The recommendations of the advisory committee are binding on the FDA and the company announced that the FDA will continue the review process, with a decision on Edukunumb’s approval on March 7, 2021. (See BIIB stock analysis on Tipperenx) To raise investor concerns, Biogen lost a patent dispute with Mylan in June 2020 for its top-selling multiple sclerosis drug, Tecfedra, which puts it in competition with the generic version of Mylan. Taxfedera’s revenue fell 15% to 95 953 million in 3Q, reflecting the impact of a number of generic entrants in the U.S. Morower, Biogen’s backbone muscle drug, Spinaraza, is experiencing a 10% drop in drug sales to 49 495. Million in 3Q. Overall, the company’s 3Q earnings fell 6.2% to 4 4.34 billion and adjusted EPS fell 3.6% to 8.84. Biogen reduced its full-year revenue outlook.2 13.2 billion – from .4 13.4 billion to .8 13.8 billion – 14 14.2 billion, assuming a “significant erosion of TECFIDERA” in 4Q. Biogen is entering into strategic collaborations to gain access to promising potential drugs. Most recently, it partnered with Sage Therapeutics to co-develop and sell Zurenolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other mental disorders and SAG-324, with a potential threshold of 1.5 billion. Payment) announced the deal.For essential tremors and other neurological disorders.Follow the Sage deal, Oppenheimer analyst Jay Olson reiterated the buy rating on Biogen with a price target of io 300. Olson explained, Probably the first category is oral therapy.Zuranolone is an active drug and given our view that there are significant market opportunities in MDD / PPD, we believe that this deal provides BIIB with some significant mid-term revenue growth and a better position to improve BIIB education results. Regardless. “Hold analysts based on 11 buys, 13 holdings and 5 sales are unanimously on one side on Street Biogen. Way to go. Biogen stocks fell 17.5% last year. After the settlement 2020, the company’s HIV Backed by factors such as portfolio and the prospect of oncology, street sentiment looks better for Gilead than Bygen. Also, unlike Bygen, Gilead pays dividends and its dividend yield is 4..6767%. To find good ideas for trading stocks at attractive valuations, visit Tiprank’s Best Stock to Buy, which unites all of Tiprank’s equity insights. Disclaimer: The views expressed in this article are those of specific analysts only. Content is intended for informational purposes only. It is very important to do your own analysis before making any investment
